Skip to main content

Table 3 Effect of TSF and placebo on Scr, BUN, UAER, eGFR and ln plasma L-FABP levels in patients with macroalbuminuria

From: Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease

Parameters Groups Baseline Week 12 Week 24
24 h UP (g/24 h) TSF 1.0 ± 0.7 0.5 ± 0.5a 0.5 ± 0.5a
Placebo 0.9 ± 0.6 0.6 ± 0.6 0.7 ± 0.7
BUN (mmol/L) TSF 6.0 ± 1.7 6.0 ± 1.7 6.0 ± 1.9
Placebo 6.1 ± 1.1 6.9 ± 1.6 7.2 ± 1.7
Scr (μmol/L) TSF 74.9 ± 20.7 72.6 ± 22.6 73.5 ± 18.9
Placebo 79.4 ± 18.2 84.0 ± 17.4 83.1 ± 16.4
eGFR (ml/min/1.73 m2) TSF 104.1 ± 32.8 102.7 ± 37.7 97.3 ± 25.8
Placebo 96.2 ± 30.0 91.3 ± 30.1 92.3 ± 32.2
ln plasma L-FABP (μg/ml) TSF 1.7 ± 1.0 1.3 ± 1.3 1.5 ± 0.9
Placebo 1.6 ± 1.2 0.8 ± 1.4 1.2 ± 1.0
  1. All values expressed as mean ± SD
  2. a P < 0.05 compared with baseline of the same group (Paired t test)
  3. Abbreviations: BUN blood urea nitrogen, eGFR estimated glomerular filtration rate, ln-serum L-FABP ln-transformed serum liver-type fatty acid binding protein, Scr serum creatinine, UAER urinary albumin excretion rate